This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kushner, B. H. Articles by Meyers, P. A. Search for Related Content PubMed PubMed Citation Articles by Kushner, B. H. Articles by Meyers, P. A. Social Bookmarking                            What's this?

How Effective Is Dose-Intensive/Myeloablative Therapy Against Ewing’s Sarcoma/Primitive Neuroectodermal Tumor Metastatic to Bone or Bone Marrow? The Memorial Sloan-Kettering Experience and a Literature Review

From the Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY.

Address reprint requests to Brian H. Kushner, MD, Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021; email: kushnerb{at}mskcc.org

PURPOSE: Attempts to improve outcomes of patients with Ewing’s sarcoma/primitive neuroectodermal tumor (ES/PNET) metastatic to bone/bone marrow (BM) have focused on chemotherapy dose intensification strategies. We now present results achieved with that approach, as carried out at Memorial Sloan-Kettering Cancer Center (MSKCC) and as reported in the literature.

PATIENTS AND METHODS: Twenty-one unselected MSKCC patients with newly diagnosed ES/PNET metastatic to bone/BM received the "P6" protocol which includes cycles of cyclophosphamide (4.2 g/m²)/doxorubicin (75 mg/m²)/vincristine and cycles of ifosfamide (9 g/m²)/etoposide (500 mg/m²). Patients in complete/very good partial remission (CR/VGPR) after P6 received myeloablative therapy with either total-body irradiation (TBI) (hyperfractionated 15 Gy)/melphalan (180 mg/m²) or thiotepa (900 mg/m²)/carboplatin (1,500 mg/m²). We reviewed the literature.

RESULTS: Only one MSKCC patient became a long-term event-free survivor; all but one relapse was in a distant site. Initial responses to P6 were CR/VGPR in 19 patients, but eight of them plus two others developed PD while receiving or shortly after completing P6. Eight patients were treated with TBI/melphalan: four relapsed 2 to 7 months after transplantation; two died early of toxicity; one died of pulmonary failure 17 months after transplantation (no evidence of ES/PNET); and one remains in CR at more than 7 years. The three patients treated with thiotepa/carboplatin relapsed 3 to 4 months after transplantation. All reports on large series of unselected patients with ES/PNET metastatic to bone/BM showed similarly unsatisfactory results. Poor outcome was seen with use of active agents for ES/PNET–cyclophosphamide, ifosfamide, doxorubicin, dactinomycin, vincristine, etoposide - at standard dosages for prolonged periods of time and at higher dosages in intensive regimens for short or prolonged periods of time. No improvements in event-free survival rates occurred with successive cooperative group or large single-institutional studies that used increasingly aggressive chemotherapeutic approaches. Inclusion of ifosfamide with or without etoposide made no difference nor did consolidation of remission with myeloablative chemoradiotherapy. Secondary leukemia emerged as a major risk with dose-intensive regimens.

CONCLUSION: The MSKCC experience and findings reported in the literature suggest that dose-intensive use of the chemotherapy agents with established activity against ES/PNET is reaching its efficacy and toxicity limits. A major impact on prognosis awaits the development of entirely novel therapies.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S HARI, T P JAIN, S THULKAR, and S BAKHSHI Imaging features of peripheral primitive neuroectodermal tumours Br. J. Radiol., December 1, 2008; 81(972): 975 - 983. [Abstract] [Full Text] [PDF]

				H. M. Lazarus, G. L. Phillips, R. H. Herzig, D. D. Hurd, S. N. Wolff, and G. P. Herzig High-Dose Melphalan and the Development of Hematopoietic Stem-Cell Transplantation: 25 Years Later J. Clin. Oncol., May 10, 2008; 26(14): 2240 - 2243. [Full Text] [PDF]

				K. K. Matthay, G. Yanik, J. Messina, A. Quach, J. Huberty, S.-C. Cheng, J. Veatch, R. Goldsby, P. Brophy, L. S. Kersun, et al. Phase II Study on the Effect of Disease Sites, Age, and Prior Therapy on Response to Iodine-131-Metaiodobenzylguanidine Therapy in Refractory Neuroblastoma J. Clin. Oncol., March 20, 2007; 25(9): 1054 - 1060. [Abstract] [Full Text] [PDF]

				O. Oberlin, A. Rey, A. S. Desfachelles, T. Philip, D. Plantaz, C. Schmitt, E. Plouvier, O. Lejars, H. Rubie, P. Terrier, et al. Impact of High-Dose Busulfan Plus Melphalan As Consolidation in Metastatic Ewing Tumors: A Study by the Societe Francaise des Cancers de l'Enfant J. Clin. Oncol., August 20, 2006; 24(24): 3997 - 4002. [Abstract] [Full Text] [PDF]

				M. Bernstein, H. Kovar, M. Paulussen, R. L. Randall, A. Schuck, L. A. Teot, and H. Juergensg Ewing's Sarcoma Family of Tumors: Current Management. Oncologist, May 1, 2006; 11(5): 503 - 519. [Abstract] [Full Text] [PDF]

				M. L. Bernstein, M. Devidas, D. Lafreniere, A.-K. Souid, P. A. Meyers, M. Gebhardt, K. Stine, R. Nicholas, E. J. Perlman, R. Dubowy, et al. Intensive Therapy With Growth Factor Support for Patients With Ewing Tumor Metastatic at Diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457--A Report From the Children's Oncology Group J. Clin. Oncol., January 1, 2006; 24(1): 152 - 159. [Abstract] [Full Text] [PDF]

				E. Hendershot Treatment Approaches for Metastatic Ewing's Sarcoma: A Review of the Literature Journal of Pediatric Oncology Nursing, November 1, 2005; 22(6): 339 - 352. [Abstract] [PDF]

				L. M. Barker, T. W. Pendergrass, J. E. Sanders, and D. S. Hawkins Survival After Recurrence of Ewing's Sarcoma Family of Tumors J. Clin. Oncol., July 1, 2005; 23(19): 4354 - 4362. [Abstract] [Full Text] [PDF]

				N. Marina and P. A. Meyers High-Dose Therapy and Stem-Cell Rescue for Ewing's Family of Tumors in Second Remission J. Clin. Oncol., July 1, 2005; 23(19): 4262 - 4264. [Full Text] [PDF]

				S. S. Myatt, C. P.F. Redfern, and S. A. Burchill p38MAPK-Dependent Sensitivity of Ewing's Sarcoma Family of Tumors to Fenretinide-Induced Cell Death Clin. Cancer Res., April 15, 2005; 11(8): 3136 - 3148. [Abstract] [Full Text] [PDF]

				A. Argon, M. Basaran, F. Yaman, Y. Dizdar, B. Sakar, H. Camlica, S. E. Bavbek, H. Ozger, E. Darendeliler, and H. Onat Ewing's Sarcoma of the Axial System in Patients Older Than 15 Years: Dismal Prognosis Despite Intensive Multiagent Chemotherapy and Aggressive Local Treatment Jpn. J. Clin. Oncol., November 1, 2004; 34(11): 667 - 672. [Abstract] [Full Text] [PDF]

				S. Batra, C. P. Reynolds, and B. J. Maurer Fenretinide Cytotoxicity for Ewing's Sarcoma and Primitive Neuroectodermal Tumor Cell Lines Is Decreased by Hypoxia and Synergistically Enhanced by Ceramide Modulators Cancer Res., August 1, 2004; 64(15): 5415 - 5424. [Abstract] [Full Text] [PDF]

				I. Gonzalez, E. J. Andreu, A. Panizo, S. Inoges, A. Fontalba, J. L. Fernandez-Luna, M. Gaboli, L. Sierrasesumaga, S. Martin-Algarra, J. Pardo, et al. Imatinib Inhibits Proliferation of Ewing Tumor Cells Mediated by the Stem Cell Factor/KIT Receptor Pathway, and Sensitizes Cells to Vincristine and Doxorubicin-Induced Apoptosis Clin. Cancer Res., January 15, 2004; 10(2): 751 - 761. [Abstract] [Full Text] [PDF]

				E. A. Kolb, B. H. Kushner, R. Gorlick, C. Laverdiere, J. H. Healey, M. P. LaQuaglia, A. G. Huvos, J. Qin, H. T. Vu, L. Wexler, et al. Long-Term Event-Free Survival After Intensive Chemotherapy for Ewing's Family of Tumors in Children and Young Adults J. Clin. Oncol., September 15, 2003; 21(18): 3423 - 3430. [Abstract] [Full Text] [PDF]

				G. Saeter ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of Ewing's sarcoma of bone Ann. Onc., August 1, 2003; 14(8): 1167 - 1168. [Full Text] [PDF]

				A. Bertuzzi, L. Castagna, A. Nozza, V. Quagliuolo, L. Siracusano, M. Balzarotti, S. Compasso, M. Alloisio, H. Soto Parra, and A. Santoro High-Dose Chemotherapy in Poor-Prognosis Adult Small Round-Cell Tumors: Clinical and Molecular Results From a Prospective Study J. Clin. Oncol., April 15, 2002; 20(8): 2181 - 2188. [Abstract] [Full Text] [PDF]